Cantourage Group SE (hereinafter “Cantourage,” ISIN: DE000A3DSV01, www.cantourage.com), a leading European company for the production and distribution of medical cannabis, has signed a long-term supply agreement for medical cannabis with the Swiss cannabis company Astrasana.
On the basis of this agreement, Cantourage will make a selected range of a total of four high-quality medical flowers with a high THC content available starting today. To start with, patients in Switzerland will be able to obtain medical cannabis flowers from the growers LOT 420, Green Karat and Breathing Green from Canada.
“We are excited about this partnership with Cantourage that will allow us to bring high-quality medical cannabis flowers with a high THC content to the Swiss market. This represents a significant step for Astrasana and a milestone in the supply of medical cannabis in Switzerland. The collaboration will allow us to meet the increasing demand for high-quality medical products and thus meet the needs of patients,” said Yves Antoniazzi, CEO of Astrasana.
“As an emerging company in the medicinal cannabis market, we are very pleased to be able to expand our footprint in Europe together with Astrasana. The range for Astrasana, which features high THC content buds, is already in high demand on the German market. As part of the partnership that has been agreed, we can now jointly set new standards in the supply of medicinal cannabis in Switzerland,” commented Sebastian Blöte, Director of Sales for Europe at Cantourage.
The partnership with Cantourage marks a significant development for the supply of medical cannabis in Switzerland. Since the legalization of medical cannabis in August 2022, a wide range of opportunities is opening up, which can now be exploited by Astrasana in collaboration with Cantourage.
For the time being, the introduction of the high-quality THC flowers, which are cultivated according to craft standards, will take place exclusively through the Rosengarten Apotheke in Zurich Bassersdorf. The latter specializes in processing and dispensing medical cannabis. Cantourage focuses on producing, releasing and distributing high-quality flowers from cultivation partners around the world according to GMP specifications. This quality and expertise will now be made available to patients in Switzerland through the cooperation with Astrasana.
About Astrasana
Astrasana Holding is an emerging Swiss cannabis company. The Group comprises an international network of companies serving all market segments in the industry. With its headquarters in Switzerland and three other companies in the UK, the Czech Republic and Japan, Astrasana employs a total of around 30 people and distributes its products in over 18 countries worldwide.
For more information: astrasana.com
About Cantourage
Cantourage is a leading European producer and distributor of cannabis-based medicinal preparations and drugs. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to become part of the growing European medical cannabis market faster, easier and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In this context, Cantourage ensures compliance with the highest European pharmaceutical quality standards at all times. The company offers pharmaceutical-grade products in all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on November 11, 2022 and is listed under ticker symbol “HIGH”.
For more information: www.cantourage.com
This announcement does not constitute a public offer or an advertisement for a public offer for sale of securities, in particular within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).
Press contacts for Cantourage:
Tonka Communications
+49 (0)176 7471 7519
cantourage@tonka-pr.com
